Ephedra Or Proactol – A Diet Pill Comparison

2010 August 27
by
Proactol

Diet pills can be very caring if you want to lose weight and diet and implementation doesn’t give you the much loved results. There many weight loss supplements available. When you search for the right diet pill you should learn about how it works, what are the side effects and if it’s safe to use in the long term.

Two well loved weight loss pills are Ephedra and Proactol. With these supplements you can lose 1-2 lbs a week which is very healthful,  you don’t want to lose more, since you don’t want to lose muscle tissues.  

Ephedra medically recognizable as thermogenic stimulant, and it reacts with your brain. It increases your heart rate and metabolism and it boost your energy level. Through this reaction your body starts to burn body stout. Ephedra has other refund, sports enhancement for athletes, treatment of asthma and treatment of hay fever.   Unfortunately Ephedra has a long list of side effects, severe skin reaction, dimness, insomnia, nausea, diarrhea, seizures, hyperthermia, and strokes. It caused over 155 deaths in the US by 2004.

Proactol is 100% untreated and organic weight loss supplement. Proactol is a stout binder and it is also an inclination suppressant. This dietary supplement has no side effects. You can use it as long as you need it. Proactol has other health refund, it reduces cholesterol level and  gives joint flexibility.

As you can see Ephedra and Proactol seem to give the same weight loss results. But a closer look reveals that Proactol is a much wiser choice. Taking into account the shifty side effects Ephedra has, you place your health in risk if you choose this product for your weight loss.

Learn more about other weight loss pills Read these simple weight loss tips if you want to lose weight and never gain it back.

Author: Jack Lancos
Article Source: EzineArticles.com
Android phones

Proactol



No comments yet

Leave a Reply

Note: You can use basic XHTML in your comments. Your email address will never be published.

Subscribe to this comment feed via RSS